Julie Yoo

Background

Julie Yoo is a General Partner on the Bio + Health team at Andreessen Horowitz (a16z), where she has led healthcare technology investments since joining the firm in October 2019 ¹². She is one of the most active healthcare-focused investors in venture capital, with a portfolio spanning AI-powered clinical tools, health infrastructure, and consumer health platforms.

Yoo studied computer science and pre-medicine as an undergraduate at MIT, then earned an M.S. in genomics from the Harvard-MIT Division of Health Sciences and Technology and an MBA from MIT Sloan School of Management ³. Her tech career began as an early member of the software engineering team at Endeca Technologies, which was later acquired by Oracle ³. She then served as VP of Product at Knome, the world’s first whole genome sequencing service for private individuals, where she worked alongside Jorge Conde (now also a General Partner at a16z) ³. She was subsequently VP of Product at Generation Health, a genetic testing benefit manager, from its inception through its acquisition by CVS Health ³.

Before joining a16z, Yoo co-founded Kyruus in 2010, a venture-backed healthtech company focused on patient access, where she served as Chief Product Officer and Board Director ⁴. At Kyruus, she helped build and scale the ProviderMatch platform — described as an “OpenTable for healthcare” — serving over 20 million patients and more than 225,000 healthcare providers across the U.S. ³⁴. Kyruus was later acquired by RevSpring ⁴.

Yoo is a Young Global Leader with the World Economic Forum and has been recognized on the Midas Brink List, as well as by Becker’s Hospital Review, Modern Healthcare, Health Data Management, MedTech Boston, and Rock Health ³.

Stated Thesis

Yoo publicly describes her investment focus as backing companies that are “transforming how we access, pay for, and experience healthcare” ³. She has articulated several core investment themes:

Healthcare as AI’s biggest beneficiary. Yoo has stated: “I genuinely believe that healthcare is the industry that will benefit the most from this wave of generative AI” ⁵. She argues that healthcare’s relative lack of prior software investment is actually an advantage, noting that “we don’t face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations” ⁶.

Administrative automation. She focuses on what she calls “administrative bloat” — the overhead of unnecessary or redundant tasks done through inefficient human labor that can be automated ⁵. She has stated that “the scarcest asset in healthcare is clinical judgment, which today only exists in the form of human doctors and nurses,” and AI can help “scale clinical judgment beyond the clinicians we have” ⁶.

Healthcare infrastructure modernization. In her essay “It’s Time to Build: Healthtech Infrastructure,” Yoo identifies the infrastructure layer as representing approximately $160 billion in enterprise value, with most existing systems relying on legacy technology lacking APIs and modern integration capabilities ⁷.

Healthy MAUs. In a16z’s Big Ideas 2026, Yoo introduced the concept of “healthy MAUs” (monthly active users) — people who are not actively sick but want to proactively track, understand, and manage their well-being — as the next high-potential customer segment for healthtech ⁸.

Consumer as payor. She sees a convergence of healthcare and fintech, where consumers become a new class of payor for preventative health services that traditional insurance ignores ⁹.

Inferred Thesis

Based on 20 verified investments, Yoo’s actual portfolio reveals a strong focus on healthcare-specific software and AI, with minimal deviation from her stated thesis — though with notable concentration patterns.

Sector breakdown (20 verified investments): - Healthcare AI / clinical AI: 7 of 20 (35%) — AKASA, Ambience Healthcare, Hippocratic AI, Bayesian Health, Counsel Health, Leona, Alchemy - Healthcare infrastructure / data: 5 of 20 (25%) — Turquoise Health, Ribbon Health, Zus Health, Tennr, Topography Health - Care delivery / virtual care: 3 of 20 (15%) — Firefly Health, Sprinter Health, Tomorrow Health - Health benefits / fintech: 2 of 20 (10%) — Thatch Health, TrueMed - Medicaid / access: 1 of 20 (5%) — Fortuna Health - Health insurance infrastructure: 1 of 20 (5%) — Aradigm - Revenue cycle: 1 of 20 (5%) — Pearl Health

Stage distribution (20 verified investments): - Seed: 10 of 20 (50%) — Turquoise Health, Fortuna Health, Thatch Health, Counsel Health, Alchemy, Leona, and others - Series A: 8 of 20 (40%) — AKASA, Ribbon Health, Zus Health, Sprinter Health, Tomorrow Health, Bayesian Health, Aradigm, Counsel Health (also Series A) - Series B: 2 of 20 (10%) — Firefly Health, Ambience Healthcare (Series A led by a16z, continued through later rounds)

Notable patterns: - AI-first thesis since 2023: Post-2023 investments are almost exclusively AI-native companies (Hippocratic AI, Counsel Health, Ambience, Leona, Alchemy), reflecting an acceleration of the AI thesis. - Operator-to-investor empathy: Yoo consistently invests in companies solving problems she personally experienced at Kyruus — patient access, provider matching, administrative burden, and healthcare data infrastructure. - Board involvement: Yoo takes board seats on most investments — confirmed board roles at AKASA, Bayesian Health, Firefly Health, Ribbon Health, Tomorrow Health, Zus Health, Turquoise Health, and Sprinter Health ³¹⁰. - Geographic concentration: Portfolio companies are primarily based in the U.S., with Leona as a notable exception operating in Latin America ¹¹. - Co-investor patterns: Frequent co-investors include GV (Google Ventures), General Catalyst, Bessemer Venture Partners, BoxGroup, and F-Prime Capital across multiple deals. - Founder profiles: Yoo backs a mix of first-time founders and experienced operators. She has specifically noted that she values founders who have “super high conviction and highly opinionated answers for why previous companies who tried this failed” ⁵.

Portfolio

In Their Own Words

“I genuinely believe that healthcare is the industry that will benefit the most from this wave of generative AI.” — Julie Yoo, Healthcare Brew interview, March 2025 ⁵

“How deeply has this individual really dug into all the things that could go right and all the things that could go wrong about building a business in this space? If they have super high conviction and highly opinionated answers for why previous companies who tried this failed, they’re going to have a competitive advantage relative to incumbents.” — Julie Yoo, on evaluating founders, Healthcare Brew, March 2025 ⁵

“Every healthcare company will eventually be a home health company.” — Julie Yoo, a16z announcement on Sprinter Health investment, October 2021 ¹⁸

“Your home will be the primary site of care.” — Julie Yoo, a16z Q&A, March 2020 ³¹

“Joy sparks for me anytime I meet a founder who has been able to achieve in months something that took us years to do at my own company.” — Julie Yoo, a16z Q&A, March 2020 ³¹

“We find ourselves now being propelled by a number of macro tailwinds that I believe make it possible to build and scale healthtech companies in a way that wasn’t possible even a few years ago.” — Julie Yoo, a16z Q&A, March 2020 ³¹

“Remember that what you are doing is an act of defying gravity. Creating and building a startup should feel very, very hard; even when it’s going well, it will still feel like it’s getting harder.” — Julie Yoo, a16z Q&A, March 2020 ³¹

“We invest in such exceptional entrepreneurs that they’re likely to be successful whether or not we’re involved.” — Julie Yoo, Healthcare Brew, March 2025 ⁵

“Software is (finally!) absolutely eating the healthcare world.” — Julie Yoo, a16z ⁷

What Founders Say

Alexander Saint-Amand, CEO of Topography Health (a16z-backed), noted that Yoo’s startup experience is a key differentiator: “[She] faced the challenges of health care and understands the reality of how difficult [electronic medical record] access is and what are the challenges, not just in privacy, but just the complexity of selling into large medical institutions and how long those things take.” — STAT News, February 2022 ¹⁴

No additional independently sourced founder testimonials found. Yoo is known across the healthcare industry for her operator background and hands-on approach with portfolio companies, but specific founder quotes beyond the above were not publicly available at the time of research.

Sources